乳腺癌-话题@MedSci

#乳腺癌#

280篇内容 | 10124人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=884679, encodeId=5b538846e98f, content=<a href='/topic/show?id=b11868811f1' target=_blank style='color:#2F92EE;'>#甘李药业#</a>宣布<a href='/topic/show?id=f336e29134' target=_blank style='color:#2F92EE;'>#FDA#</a>授予其细胞周期蛋白依赖性激酶 4/6（CDK4/6）抑制剂GLR2007<a href='/topic/show?id=dad04542ede' target=_blank style='color:#2F92EE;'>#孤儿药#</a>资格，用于治疗包括<a href='/topic/show?id=01858406438' target=_blank style='color:#2F92EE;'>#胶质母细胞瘤#</a>（GBM）在内的<a href='/topic/show?id=8d2452942c2' target=_blank style='color:#2F92EE;'>#恶性胶质瘤#</a>，有些迷惑了。CDK4/6不是用于<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>，<a href='/topic/show?id=08f236865a8' target=_blank style='color:#2F92EE;'>#卵巢癌#</a>的吗？, objectTitle=甘李药业CDK4/6抑制剂获FDA孤儿药资格，治疗恶性胶质瘤, objectType=article, longId=200588, objectId=285f20058863, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020911/1599837648162_2119349.jpg, objectUrl=/article/show_article.do?id=285f20058863, replyNumber=0, likeNumber=295, createdTime=2020-09-12, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=285f20058863, moduleTitle=甘李药业CDK4/6抑制剂获FDA孤儿药资格，治疗恶性胶质瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=285f20058863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=881890, encodeId=bd2088189048, content=对于<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者来说，明确保乳手术切缘既维护了患者保乳意愿也降低再手术风险。, objectTitle=JAMA Surg：2014 SSO-ASTRO乳腺癌保乳手术切缘新指南降低了患者再手术风险, objectType=article, longId=200126, objectId=5af92001265a, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202091/1598958576897_2051781.jpg, objectUrl=/article/show_article.do?id=5af92001265a, replyNumber=0, likeNumber=142, createdTime=2020-09-01, rootId=0, userName=Sunny orchard, userId=1a335163906, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5af92001265a, moduleTitle=JAMA Surg：2014 SSO-ASTRO乳腺癌保乳手术切缘新指南降低了患者再手术风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5af92001265a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=880631, encodeId=35fa880631c0, content=对于可以接受<a href='/topic/show?id=4bf12e14928' target=_blank style='color:#2F92EE;'>#保乳术#</a>治疗的早期<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>患者，术中接受单次放疗的治疗效果与术后体外放射治疗相当。看来<a href='/topic/show?id=2540609806b' target=_blank style='color:#2F92EE;'>#术中放疗#</a>与<a href='/topic/show?id=e73510384667' target=_blank style='color:#2F92EE;'>#术中化疗#</a>可能有别，术中化疗对于及时杀伤肿瘤细胞，可能是有用的，但是术中放疗可能并不阻断因为手术过程造成的少量肿瘤细胞的播散吧。, objectTitle=BMJ：保乳手术术中放疗治疗早期乳腺癌, objectType=article, longId=199823, objectId=59a1199823a4, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/101r.jpg, objectUrl=/article/show_article.do?id=59a1199823a4, replyNumber=0, likeNumber=171, createdTime=2020-08-29, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59a1199823a4, moduleTitle=BMJ：保乳手术术中放疗治疗早期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59a1199823a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=880630, encodeId=e336880630f3, content=没有完全理解这个机制。一般来说，<a href='/topic/show?id=c55098e5612' target=_blank style='color:#2F92EE;'>#雌激素#</a>应该是不利的，应该用雌激素拮抗剂才对，为什么用受体激动剂<a href='/topic/show?id=f465103845bc' target=_blank style='color:#2F92EE;'>#TTC-352#</a>来治疗<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>呢？看了一下原文，这样描述：TTC-352 is a selective human estrogen receptor partial agonist (ShERPA). TTC-352 is designed to treat metastatic ER+ breast cancers that have progressed on first-line endocrine therapy and a CDK4/6 inhibitor. TTC-352 is expected to be effective in breast cancer patients that develop resistance to endocrine therapy (est. 625,000 patients). 确实是雌激素受体部分激动剂(ShERPA)，以后再多研究研究, objectTitle=雌激素受体激动剂TTC-352，一种有治疗潜力的抗乳腺癌药物, objectType=article, longId=200041, objectId=58b020004184, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020829/1598693522463_5295902.jpeg, objectUrl=/article/show_article.do?id=58b020004184, replyNumber=0, likeNumber=203, createdTime=2020-08-29, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58b020004184, moduleTitle=雌激素受体激动剂TTC-352，一种有治疗潜力的抗乳腺癌药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58b020004184)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=808988, encodeId=b662808988bc, content=<a href='/topic/show?id=f7bd103431f8' target=_blank style='color:#2F92EE;'>#鼻喷剂#</a>是极有潜力的剂型，目前有很多药物均有这种剂型，包括治疗<a href='/topic/show?id=09f0e1554e6' target=_blank style='color:#2F92EE;'>#癫痫#</a>，<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>等, objectTitle=Ann Allergy Asthma Immunol：鼻内抗组胺治疗过敏性鼻炎要优于口服H1抗组胺 , objectType=article, longId=198879, objectId=ddac1988e94c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202086/1596693585361_1935437.jpg, objectUrl=/article/show_article.do?id=ddac1988e94c, replyNumber=1, likeNumber=459, createdTime=2020-08-14, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ddac1988e94c, moduleTitle=Ann Allergy Asthma Immunol：鼻内抗组胺治疗过敏性鼻炎要优于口服H1抗组胺 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ddac1988e94c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=808660, encodeId=579780866032, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>的研究越来越细分，关注到一些细分人群。如<a href='/topic/show?id=d2d2103e8909' target=_blank style='color:#2F92EE;'>#三阳性乳腺癌#</a><a href='/topic/show?id=b94a103e903e' target=_blank style='color:#2F92EE;'>#HR+HER2+#</a>，或<a href='/topic/show?id=3f6c103e916d' target=_blank style='color:#2F92EE;'>#ER+PR-乳腺癌#</a>或<a href='/topic/show?id=0d70103e92d3' target=_blank style='color:#2F92EE;'>#AR+三阴性乳腺癌#</a>等等，这些都值得同道关注, objectTitle=三阳性乳腺癌，抗HER2联合化疗，还是联合内分泌治疗？, objectType=article, longId=198990, objectId=55ce1989908b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/408.jpg, objectUrl=/article/show_article.do?id=55ce1989908b, replyNumber=0, likeNumber=2, createdTime=2020-08-13, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55ce1989908b, moduleTitle=三阳性乳腺癌，抗HER2联合化疗，还是联合内分泌治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55ce1989908b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=808655, encodeId=a132808655ba, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>BRCA1/2突变，用<a href='/topic/show?id=41f54454653' target=_blank style='color:#2F92EE;'>#奥拉帕利#</a>很合时宜，但是用PD-L1，是值得怀疑的，对于这样明确突变的人群，很少看到PD-1、或PD-L1获益的。在肺癌中EGFR突变的患者，原则上不宜用免疫治疗的。, objectTitle=Lancet oncol：奥拉帕利联合Durvalumab治疗BRCA突变的转移性乳腺癌, objectType=article, longId=199142, objectId=daaa19914221, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/193.jpg, objectUrl=/article/show_article.do?id=daaa19914221, replyNumber=0, likeNumber=182, createdTime=2020-08-13, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=daaa19914221, moduleTitle=Lancet oncol：奥拉帕利联合Durvalumab治疗BRCA突变的转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=daaa19914221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=808397, encodeId=1cbf80839ea8, content=广大乳癌患者**<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, objectTitle=TUKYSA（tucatinib）在澳大利亚获得批准，用于治疗转移性HER2阳性乳腺癌, objectType=article, longId=199343, objectId=af9d1993432d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020812/1597244632127_5295902.jpeg, objectUrl=/article/show_article.do?id=af9d1993432d, replyNumber=0, likeNumber=141, createdTime=2020-08-13, rootId=0, userName=Psycho.Dr Du, userId=a8fb2299762, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af9d1993432d, moduleTitle=TUKYSA（tucatinib）在澳大利亚获得批准，用于治疗转移性HER2阳性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af9d1993432d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=803728, encodeId=9842803e28d8, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>与心血管千丝万缕, objectTitle=Nat Med：警惕！心血管疾病会加速乳腺癌复发, objectType=article, longId=197893, objectId=82c619e893b6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020721/1595332387083_5295905.jpg, objectUrl=/article/show_article.do?id=82c619e893b6, replyNumber=0, likeNumber=161, createdTime=2020-07-21, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82c619e893b6, moduleTitle=Nat Med：警惕！心血管疾病会加速乳腺癌复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82c619e893b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=803351, encodeId=71b2803351ff, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>, objectTitle=李青：乳腺癌靶向治疗及进展, objectType=video, longId=4270, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://medsci-video.oss-cn-shanghai.aliyuncs.com/upload/content/day_181113/big/201811132053108218.png, objectUrl=null, replyNumber=0, likeNumber=106, createdTime=2020-07-19, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a91ef442e0654, moduleTitle=李青：乳腺癌靶向治疗及进展, moduleType=video, hrefUrl=)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=803283, encodeId=b4b880328301, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>禁食治疗, objectTitle=NATURE：饮食限制配合激素治疗可长效促进乳腺癌消退, objectType=article, longId=197754, objectId=2e1e19e75487, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/2020719/1595129006994_5295900.jpg, objectUrl=/article/show_article.do?id=2e1e19e75487, replyNumber=0, likeNumber=142, createdTime=2020-07-19, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e1e19e75487, moduleTitle=NATURE：饮食限制配合激素治疗可长效促进乳腺癌消退, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e1e19e75487)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=803070, encodeId=501c8030e01c, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>与心梗关联起来了, objectTitle=Nat Med：心脏病或促进乳腺癌转移！心脏病会重编程免疫系统，导致免疫力下降，促进乳腺癌进展和转移, objectType=article, longId=197655, objectId=0de419e655aa, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20200716/765a34313bd749d3b810e4e36265c74c.jpg, objectUrl=/article/show_article.do?id=0de419e655aa, replyNumber=0, likeNumber=145, createdTime=2020-07-17, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0de419e655aa, moduleTitle=Nat Med：心脏病或促进乳腺癌转移！心脏病会重编程免疫系统，导致免疫力下降，促进乳腺癌进展和转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0de419e655aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=802351, encodeId=fdd48023511c, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>卵巢功能抑制的分析，这里面算是大全呢, objectTitle=乳腺癌卵巢功能抑制(OFS) 在乳腺癌中是是非非, objectType=article, longId=197345, objectId=aea719e3451b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20200709/6e4d5796a67e4585a05b59ff73212345.jpg, objectUrl=/article/show_article.do?id=aea719e3451b, replyNumber=0, likeNumber=169, createdTime=2020-07-10, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aea719e3451b, moduleTitle=乳腺癌卵巢功能抑制(OFS) 在乳腺癌中是是非非, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aea719e3451b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=800726, encodeId=f12c800e26a1, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>双妥方案皮下使用, objectTitle=FDA批准罗氏的乳腺癌双靶向HER2抗体组合：帕妥珠单抗与曲妥珠单抗, objectType=article, longId=196865, objectId=2899196865f2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202071/1593555684130_5085975.jpg, objectUrl=/article/show_article.do?id=2899196865f2, replyNumber=0, likeNumber=138, createdTime=2020-07-01, rootId=0, userName=mswert122, userId=2a791737770, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2899196865f2, moduleTitle=FDA批准罗氏的乳腺癌双靶向HER2抗体组合：帕妥珠单抗与曲妥珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2899196865f2)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=799797, encodeId=3860e997977e, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a>乳腺肿瘤发展还是很迅速的，希望在三阴乳腺也有突破。, objectTitle=Pre-ASCO 乳腺癌治疗的现状与未来, objectType=video, longId=4487, objectId=null, topicUrl=null, isHasObj=0, objectCover=https://medsci-video.oss-cn-shanghai.aliyuncs.com/upload/content/day_200528/big/202005281532575595.png, objectUrl=null, replyNumber=0, likeNumber=81, createdTime=2020-06-25, rootId=0, userName=mswert122, userId=2a791737770, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0c97f448e8d5, moduleTitle=Pre-ASCO 乳腺癌治疗的现状与未来, moduleType=video, hrefUrl=)], followStatus=false, userIsMember=true, type=1, lengthMark=0)] 梅斯话题小助手

让乳腺癌成为不会危及生命的慢病！

2020-05-29

lovetcm (审核中...)

前往app查看评论内容

#甘李药业#宣布#FDA#授予其细胞周期蛋白依赖性激酶 4/6（CDK4/6）抑制剂GLR2007#孤儿药#资格，用于治疗包括#胶质母细胞瘤#（GBM）在内的#恶性胶质瘤#，有些迷惑了。CDK4/6不是用于#乳腺癌#，#卵巢癌#的吗？

甘李药业CDK4/6抑制剂获FDA孤儿药资格，治疗恶性胶质瘤

2020-09-12

Sunny orchard (审核中...)

前往app查看评论内容

对于#乳腺癌#患者来说，明确保乳手术切缘既维护了患者保乳意愿也降低再手术风险。

JAMA Surg：2014 SSO-ASTRO乳腺癌保乳手术切缘新指南降低了患者再手术风险

2020-09-01

lovetcm (审核中...)

前往app查看评论内容

对于可以接受#保乳术#治疗的早期#乳腺癌#患者，术中接受单次放疗的治疗效果与术后体外放射治疗相当。看来#术中放疗#与#术中化疗#可能有别，术中化疗对于及时杀伤肿瘤细胞，可能是有用的，但是术中放疗可能并不阻断因为手术过程造成的少量肿瘤细胞的播散吧。

BMJ：保乳手术术中放疗治疗早期乳腺癌

2020-08-29

lovetcm (审核中...)

前往app查看评论内容

全文收起没有完全理解这个机制。一般来说，#雌激素#应该是不利的，应该用雌激素拮抗剂才对，为什么用受体激动剂#TTC-352#来治疗#乳腺癌#呢？看了一下原文，这样描述：TTC-352 is a selective human estrogen receptor partial agonist (ShERPA). TTC-352 is designed to treat metastatic ER+ breast cancers that have progressed on first-line endocrine therapy and a CDK4/6 inhibitor. TTC-352 is expected to be effective in breast cancer patients that develop resistance to endocrine therapy (est. 625,000 patients). 确实是雌激素受体部分激动剂(ShERPA)，以后再多研究研究

雌激素受体激动剂TTC-352，一种有治疗潜力的抗乳腺癌药物

2020-08-29

lovetcm (审核中...)

前往app查看评论内容

#鼻喷剂#是极有潜力的剂型，目前有很多药物均有这种剂型，包括治疗#癫痫#，#乳腺癌#等

Ann Allergy Asthma Immunol：鼻内抗组胺治疗过敏性鼻炎要优于口服H1抗组胺

2020-08-14

lovetcm (审核中...)

前往app查看评论内容

#乳腺癌#的研究越来越细分，关注到一些细分人群。如#三阳性乳腺癌##HR+HER2+#，或#ER+PR-乳腺癌#或#AR+三阴性乳腺癌#等等，这些都值得同道关注

三阳性乳腺癌，抗HER2联合化疗，还是联合内分泌治疗？

2020-08-13

lovetcm (审核中...)

前往app查看评论内容

#乳腺癌#BRCA1/2突变，用#奥拉帕利#很合时宜，但是用PD-L1，是值得怀疑的，对于这样明确突变的人群，很少看到PD-1、或PD-L1获益的。在肺癌中EGFR突变的患者，原则上不宜用免疫治疗的。

Lancet oncol：奥拉帕利联合Durvalumab治疗BRCA突变的转移性乳腺癌

2020-08-13

Psycho.Dr Du (审核中...)

前往app查看评论内容

广大乳癌患者**#乳腺癌#

TUKYSA（tucatinib）在澳大利亚获得批准，用于治疗转移性HER2阳性乳腺癌

2020-08-13

lovetcm (审核中...)

前往app查看评论内容

#乳腺癌#与心血管千丝万缕

Nat Med：警惕！心血管疾病会加速乳腺癌复发

2020-07-21

lovetcm (审核中...)

前往app查看评论内容

#乳腺癌#

李青：乳腺癌靶向治疗及进展

2020-07-19

lovetcm (审核中...)

前往app查看评论内容

#乳腺癌#禁食治疗

NATURE：饮食限制配合激素治疗可长效促进乳腺癌消退

2020-07-19

lovetcm (审核中...)

前往app查看评论内容

#乳腺癌#与心梗关联起来了

Nat Med：心脏病或促进乳腺癌转移！心脏病会重编程免疫系统，导致免疫力下降，促进乳腺癌进展和转移

2020-07-17

lovetcm (审核中...)

前往app查看评论内容

#乳腺癌#卵巢功能抑制的分析，这里面算是大全呢

乳腺癌卵巢功能抑制(OFS) 在乳腺癌中是是非非

2020-07-10

(审核中...)

前往app查看评论内容

#乳腺癌#双妥方案皮下使用

FDA批准罗氏的乳腺癌双靶向HER2抗体组合：帕妥珠单抗与曲妥珠单抗

2020-07-01

(审核中...)

前往app查看评论内容

#乳腺癌#乳腺肿瘤发展还是很迅速的，希望在三阴乳腺也有突破。

Pre-ASCO 乳腺癌治疗的现状与未来

2020-06-25

科室
- - 订阅+
  - 更多科室
工具
服务